Cystic fibrosis lung disease: Genetic influences, microbial interactions, and radiological assessment

Pediatric Radiology

Volumn 35, Issue 8, 2005, Pages 739-757

  Moskowitz, Samuel M ^a   Gibson, Ronald L ^a   Effmann, Eric L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Chest radiograph; Current therapies; Cystic fibrosis; Functional imaging; Genetics; High resolution CT; Microbiology

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BRONCHODILATING AGENT; CEFTAZIDIME; CEPHALOSPORIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENISTEIN; GENTAMICIN; LEAD; MUCOLYTIC AGENT; PLACEBO; RADIOISOTOPE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AIRWAY OBSTRUCTION; ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BRONCHIECTASIS; BRONCHOPULMONARY ASPERGILLOMA; CHROMOSOME 7; CHROMOSOME ARM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; EARLY DIAGNOSIS; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE THERAPY; GENETIC VARIABILITY; HEREDITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOMOZYGOSITY; HUMAN; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; LUNG CLEARANCE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG INFECTION; LUNG SCINTISCANNING; MORBIDITY; MORTALITY; MUTATIONAL ANALYSIS; NONVIRAL GENE DELIVERY SYSTEM; OBSERVER VARIATION; OUTCOMES RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RESPIRATORY TRACT INFECTION; REVIEW; RISK REDUCTION; SCORING SYSTEM; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERMOREGULATION; THORAX RADIOGRAPHY; VIRAL GENE DELIVERY SYSTEM;

ALLELES; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; PHENOTYPE;

EID: 23644462552     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-005-1445-3     Document Type: Review

References (180)

1. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918-951 10.1164/rccm.200304-505SO
2. Cystic Fibrosis Foundation Patient Registry (2004) 2003 Annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda
3. Cohn JA, Friedman KJ, Noone PG, et al (1998) Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 339:653-658 10.1056/NEJM199809033391002
4. Sharer N, Schwarz M, Malone G, et al (1998) Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 339:645-652 10.1056/NEJM199809033391001
5. Chillon M, Casals T, Mercier B, et al (1995) Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332:1475-1480 10.1056/NEJM199506013322204
6. Bombieri C, Benetazzo M, Saccomani A, et al (1998) Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet 103:718-722 10.1007/s004390050897
7. Wang X, Moylan B, Leopold DA, et al (2000) Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284:1814-1819 10.1001/jama.284.14.1814
8. Moskowitz SM, Gibson RL, Sternen DL, et al (2004) CFTR-related disorders. In: GeneReviews at GeneTests: Medical genetics information resource (online database). Available at http://www.genetests.org. Cited 18 July 2004
9. Kerem BS, Rommens JM, Buchanan JA, et al (1989) Identification of the cystic fibrosis gene: Genetic analysis. Science 245:1073-1080 1:CAS:528:DyaL1MXlvVylt74%3D
10. Rommens JM, Iannuzzi MC, Kerem BS, et al (1989) Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 245:1059-1065 1:CAS:528:DyaL1MXls1yms7c%3D
11. Riordan JR, Rommens JM, Kerem BS, et al (1989) Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245:1066-1073 1:CAS:528:DyaK3cXhvFarur0%3D
12. Kulich M, Rosenfeld M, Goss CH, et al (2003) Improved survival among young patients with cystic fibrosis. J Pediatr 142:631-636
13. Tsui LC, Zielenski J (2004) Cystic fibrosis mutation database. Hospital for Sick Children (Toronto, Canada). Available at http://www.genet.sickkids.on.ca/cftr/. Cited 18 July 2004
14. Wang X, Myers A, Saiki RK, et al (2002) Development and evaluation of a PCR-based, line probe assay for the detection of 58 alleles in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Clin Chem 48:1121-1123 1:CAS:528:DC%2BD38XltVWnsL0%3D
15. Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254 10.1016/ 0092-8674(93)90353-R
16. McKone EF, Emerson SS, Edwards KL, et al (2003) Effect of genotype on phenotype and mortality in cystic fibrosis: A retrospective cohort study. Lancet 361:1671-1676 10.1016/S0140-6736(03)13368-5
17. Mak V, Zielenski J, Tsui LC, et al (1999) Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. JAMA 281:2217-2224 10.1001/jama.281.23.2217
18. Kiesewetter S, Macek M Jr, Davis C, et al (1993) A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 5:274-278 10.1038/ng1193-274
19. Friedman KJ, Heim RA, Knowles MR, et al (1997) Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: Association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease. Hum Mutat 10:108-115 10.1002/(SICI)1098-1004(1997)10:2<108::AID-HUMU3>3.0.CO;2-G
20. Dork T, Dworniczak B, Aulehla-Scholz C, et al (1997) Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 100:365-377 10.1007/s004390050518
21. Cuppens H, Lin W, Jaspers M, et al (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487-496 1:CAS:528:DyaK1cXmtF2hug%3D%3D
22. Groman JD, Hefferon TW, Casals T, et al (2004) Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 74:176-179 10.1086/381001
23. Noone PG, Pue CA, Zhou Z, et al (2000) Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 162:1919-1924 1:STN:280:DC%2BD3M%2FkvF2htg%3D%3D
24. Brock DJ, Gilfillan A, Holloway S (1998) The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies. Clin Genet 53:47-49 10.1034/j.1399-0004.1998.531530109.x
25. Witt DR, Schaefer C, Hallam P, et al (1996) Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 58:823-835 1:STN:280:BymB38%2FitlI%3D
26. Rubin BK (1990) Exposure of children with cystic fibrosis to environmental tobacco smoke. N Engl J Med 323:782-788 1:STN:280:By%2BA28zisFw%3D
27. Campbell PW 3rd, Parker RA, Roberts BT, et al (1992) Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr 120:261-264 17358230
28. Kovesi T, Corey M, Levison H (1993) Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis 148:1266-1271 1:STN:280:ByuD2MjntVQ%3D
29. Drumm ML (2001) Modifier genes and variation in cystic fibrosis. Respir Res 2:125-128 10.1186/rr47
30. Frangolias DD, Ruan J, Wilcox PJ, et al (2003) Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 29:390-396 10.1165/rcmb.2002-0271OC
31. Grasemann H, vans Gravesande KS, Buscher R, et al (2003) Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 167:390-394 10.1164/rccm.200202-155OC
32. Garred P, Pressler T, Madsen HO, et al (1999) Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 104:431-437 1:CAS:528:DyaK1MXltlekur4%3D
33. Hull J, Thomson AH (1998) Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 53:1018-1021 1:STN:280:DyaK1M3htV2ktw%3D%3D
34. Drumm ML, Konstan MW, Goddard K, et al (2004) A candidate gene screen for modifiers of CF lung disease. Am J Respir Crit Care Med 169:A582
35. Lim M, Zeitlin PL (2001) Therapeutic strategies to correct malfunction of CFTR. Paediatr Respir Rev 2:159-164 10.1053/prrv.2000.0124
36. Clancy JP, Bebok Z, Ruiz F, et al (2001) Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163:1683-1692 1:STN:280:DC%2BD3MvgsVSquw%3D%3D
37. Wilschanski M, Yahav Y, Yaacov Y, et al (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433-1441 10.1056/NEJMoa022170
38. Wilschanski M, Famini C, Blau H, et al (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860-865 1:STN:280:DC%2BD3c7nsl2isA%3D%3D
39. Zeitlin PL, Diener-West M, Rubenstein RC, et al (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6:119-126 10.1006/mthe.2002.0639
40. Lim M, McKenzie K, Floyd AD, et al (2004) Modulation of DeltaF508 CFTR trafficking and function with 4-PBA and flavonoids. Am J Respir Cell Mol Biol 31:351-357 10.1165/rcmb.2002-0086OC
41. Zar H, Saiman L, Quittell L, et al (1995) Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 126:230-233 1:STN:280:ByqC2cjhtFc%3D
42. Tirouvanziam R, de Bentzmann S, Hubeau C, et al (2000) Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 23:121-127 1:CAS:528:DC%2BD3cXmt1OgtLc%3D
43. Smith JJ, Travis SM, Greenberg EP, et al (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229-236 10.1016/S0092-8674(00)81099-5
44. Cole AM, Ganz T (2002) Antimicrobial peptides and proteins in the CF airway. Methods Mol Med 70:447-464 1:CAS:528:DC%2BD38Xisl2js7g%3D
45. Matsui H, Grubb BR, Tarran R, et al (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005-1015 10.1016/S0092-8674(00)81724-9
46. Worlitzsch D, Tarran R, Ulrich M, et al (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317-325 10.1172/JCI200213870
47. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10:487-493 10.1038/nm1028
48. Khan TZ, Wagener JS, Bost T, et al (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075-1082 1:STN:280:ByqB3M7jtF0%3D
49. LiPuma JJ, Spilker T, Gill LH, et al (2001) Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 164:92-96 1:STN:280:DC%2BD3MznvVOnuw%3D%3D
50. Chen JS, Witzmann KA, Spilker T, et al (2001) Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 139:643-649 10.1067/mpd.2001.118430
51. LiPuma JJ, Spilker T, Coenye T, et al (2002) An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 359:2002-2003 10.1016/ S0140-6736(02)08836-0
52. Mahenthiralingam E, Vandamme P, Campbell ME, et al (2001) Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: Virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 33:1469-1475 10.1086/322684
53. Manno G, Dalmastri C, Tabacchioni S, et al (2004) Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian cystic fibrosis center. J Clin Microbiol 42:1491-1497 10.1128/JCM.42.4.1491-1497.2004
54. Olivier KN, Weber DJ, Wallace RJ Jr, et al (2003) Nontuberculous mycobacteria I: Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167:828-834 10.1164/rccm.200207-678OC
55. Olivier KN, Weber DJ, Lee JH, et al (2003) Nontuberculous mycobacteria. II. Nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 167:835-840 10.1164/rccm.200207-679OC
56. Yoon SS, Hennigan RF, Hilliard GM, et al (2002) Pseudomonas aeruginosa anaerobic respiration in biofilms: Relationships to cystic fibrosis pathogenesis. Dev Cell 3:593-603 10.1016/S1534-5807(02)00295-2
57. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: A common cause of persistent infections. Science 284:1318-1322 10.1126/ science.284.5418.1318
58. Drenkard E, Ausubel FM (2002) Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743 10.1038/416740a
59. Prince AS (2002) Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 347:1110-1111 10.1056/NEJMcibr021776
60. Hoiby N, Krogh Johansen H, Moser C, et al (2001) Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 3:23-35 10.1016/S1286-4579(00)01349-6
61. Mah TF, Pitts B, Pellock B, et al (2003) A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310 10.1038/ nature02122
62. Mah TF, O'Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34-39 10.1016/ S0966-842X(00)01913-2
63. Bagge N, Hentzer M, Andersen JB, et al (2004) Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 48:1168-1174 10.1128/ AAC.48.4.1168-1174.2004
64. Jensen ET, Kharazmi A, Garred P, et al (1993) Complement activation by Pseudomonas aeruginosa biofilms. Microb Pathog 15:377-388 10.1006/ mpat.1993.1087
65. Meluleni GJ, Grout M, Evans DJ, et al (1995) Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 155:2029-2038 1:C0AS:528:DyaK2MXnsVShsrw%3D
66. Singh PK, Schaefer AL, Parsek MR, et al (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764 10.1038/35037627
67. VanDevanter DR, Van Dalfsen JM (2005) How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? Pediatr Pulmonol (in press)
68. Ordonez CL, Henig NR, Mayer-Hamblett N, et al (2003) Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 168:1471-1475 10.1164/ rccm.200306-731OC
69. Smith AL, Doershuk C, Goldmann D, et al (1999) Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 134:413-421 1:CAS:528:DyaK1MXislarsbY%3D
70. Rosenfeld M, Emerson J, Williams-Warren J, et al (2001) Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 139:359-365 10.1067/ mpd.2001.117288
71. Chan C, Burrows LL, Deber CM (2004) Helix induction in antimicrobial peptides by alginate in biofilms. J Biol Chem 279:38749-38754 10.1074/ jbc.M406044200
72. Nivens DE, Ohman DE, Williams J, et al (2001) Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol 183:1047-1057 10.1128/JB.183.3.1047-1057.2001
73. Hentzer M, Teitzel GM, Balzer GJ, et al (2001) Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 183:5395-5401 10.1128/JB.183.18.5395-5401.2001
74. Wozniak DJ, Wyckoff TJ, Starkey M, et al (2003) Alginate is not a significant component of the extracellular polysaccharide matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 100:7907-7912 10.1073/pnas.1231792100
75. Boucher JC, Yu H, Mudd MH, et al (1997) Mucoid Pseudomonas aeruginosa in cystic fibrosis: Characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 65:3838-3846 1:CAS:528:DyaK2sXlvFKntrg%3D
76. Deretic V, Schurr MJ, Yu H (1995) Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Trends Microbiol 3:351-356 10.1016/S0966-842X(00)88974-X
77. Mahenthiralingam E, Campbell ME, Speert DP (1994) Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 62:596-605 1:CAS:528:DyaK2cXhs1Wnt78%3D
78. Haas B, Murphy E, Castignetti D (1991) Siderophore synthesis by mucoid Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Can J Microbiol 37:654-657 1:CAS:528:DyaK3MXmtVaqsLc%3D
79. De Vos D, De Chial M, Cochez C et al (2001) Study of pyoverdine type and production by Pseudomonas aeruginosa isolated from cystic fibrosis patients: Prevalence of Type II pyoverdine isolates and accumulation of pyoverdine-negative mutations. Arch Microbiol 175:384-388 10.1007/ s002030100278
80. Hancock RE, Mutharia LM, Chan L, et al (1983) Pseudomonas aeruginosa isolates from patients with cystic fibrosis: A class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 42:170-177 1:CAS:528:DyaL3sXlvFWhs7o%3D
81. Schiller NL, Alazard MJ, Borowski RS (1984) Serum sensitivity of a Pseudomonas aeruginosa mucoid strain. Infect Immun 45:748-755 1:STN:280:BiuB1cjosFc%3D
82. Eichler I, Joris L, Hsu YP, et al (1989) Nonopsonic antibodies in cystic fibrosis Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. J Clin Invest 84:1794-1804 1:CAS:528:DyaK3cXps1Ogtw%3D%3D
83. Stevens DA, Moss RB, Kurup VP, et al (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis - State of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37[Suppl 3]:S225-S264 10.1086/376525
84. Burns JL, Van Dalfsen JM, Shawar RM, et al (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190-1196 1190-1196 10.1086/314727
85. Jensen T, Pedersen SS, Garne S, et al (1987) Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19:831-838 1:STN:280:BiiB2sbmtlM%3D
86. Nepomuceno IB, Esrig S, Moss RB (1999) Allergic bronchopulmonary aspergillosis in cystic fibrosis: Role of atopy and response to itraconazole. Chest 115:364-370 10.1378/chest.115.2.364
87. Knowles MR, Boucher RC (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109:571-577 10.1172/JCI200215217
88. Schaad UB, Lang AB, Wedgwood J, et al (1990) Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: Correlation to disease, subclass distribution, and experimental protective capacity. Pediatr Res 27:508-513 1:STN:280:By%2BB28rmslQ%3D
89. Winnie GB, Cowan RG (1991) Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: Correlations between anti- Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 10:92-100 1:STN:280:By6B3s3ovVc%3D
90. Kosorok MR, Zeng L, West SE, et al (2001) Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32:277-287 10.1002/ppul.2009.abs
91. Pier GB, Saunders JM, Ames P, et al (1987) Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med 317:793-798 1:STN:280:BiiA3MrisVM%3D
92. Frederiksen B, Koch C, Hoiby N (1999) Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 28:159-166 10.1002/ (SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1
93. Ratjen F (2001) Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 17:93-96 10.1016/ S0924-8579(00)00333-2
94. Regelmann WE, Elliott GR, Warwick WJ, et al (1990) Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodila0tors and chest physiotherapy alone. Am Rev Respir Dis 141:914-921 1:STN:280:By%2BB38rksVw%3D
95. Gold R, Carpenter S, Heurter H, et al (1987) Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 111:907-913 1:STN:280:BieD287oslI%3D
96. Breen L, Aswani N (2001) Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev: CD002767
97. Wiesemann HG, Steinkamp G, Ratjen F, et al (1998) Placebo-controlled, double-blind, randomized study of aerosolized tob0ramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25:88-92 10.1002/ (SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J
98. Ratjen F, Doring G, Nikolaizik WH (2001) Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358:983-984 10.1016/S0140-6736(01)06124-4
99. Griese M, Muller I, Reinhardt D (2002) Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 7:79-80 11891148
100. Rosenfeld M, Ramsey BW, Gibson RL (2003) Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management. Curr Opin Pulm Med 9:492-497 10.1097/00063198-200311000-00008
101. Stephens D, Garey N, Isles A, et al (1983) Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 2:209-211 1:STN:280:BiyB2cnosFQ%3D
102. Schaad UB, Wedgwood-Krucko J, Suter S, et al (1987) Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 111:599-605 1:STN:280:BieD3M%2Fjs1w%3D
103. Gibson RL, Emerson J, McNamara S, et al (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167:841-849 10.1164/ rccm.200208-855OC
104. Stutman HR, Lieberman JM, Nussbaum E, et al (2002) Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomized controlled trial. J Pediatr 140:299-305 10.1067/ mpd.2002.121930
105. Ratjen F, Comes G, Paul K, et al (2001) Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 31:13-16 10.1002/ 1099-0496(200101)31:1<13::AID-PPUL1001>3.0.CO;2-N
106. Elphick HE, Tan A (2001) Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev: CD002007
107. Steinkamp G, Tummler B, Malottke R, et al (1989) Treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Arch Dis Child 64:1022-1028 1:STN:280:By%2BC1MjitFA%3D
108. Ramsey BW, Pepe MS, Quan JM, et al (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23-30 10.1056/ NEJM199901073400104
109. Smith AL, Fiel SB, Mayer-Hamblett N, et al (2003) Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest 123:1495-1502 10.1378/chest.123.5.1495
110. Saiman L, Mehar F, Niu WW, et al (1996) Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23:532-537 1:CAS:528:DyaK28XlvVGgtbk%3D
111. Lang BJ, Aaron SD, Ferris W, et al (2000) Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 162:2241-2245 1:STN:280:DC%2BD3M7gt1yqtg%3D%3D
112. Aaron SD, Ferris W, Ramotar K, et al (2002) Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 40:4172-4179 10.1128/ JCM.40.11.4172-4179.2002
113. Moskowitz SM, Foster JM, Emerson J, et al (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42:1915-1922 10.1128/ JCM.42.5.1915-1922.2004
114. Saiman L, Siegel J (2004) Infection control in cystic fibrosis. Clin Microbiol Rev 17:57-71 10.1128/CMR.17.1.57-71.2004
115. Farrell PM, Shen G, Splaingard M, et al (1997) Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 100:E2 10.1542/peds.100.5.e2
116. Thomas J, Cook DJ, Brooks D (1995) Chest physical therapy management of patients with cystic fibrosis. A meta-analysis. Am J Respir Crit Care Med 151:846-850 1:STN:280:ByqC1cjksVA%3D
117. Oermann CM, Sockrider MM, Giles D, et al (2001) Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: A pilot study. Pediatr Pulmonol 32:372-377 10.1002/ppul.1146
118. Konstan MW, Stern RC, Doershuk CF (1994) Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 124:689-693 1:STN:280:ByuB3s7js1E%3D
119. Ramsey BW, Astley SJ, Aitken ML, et al (1993) Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 148:145-151 1:STN:280:ByyA3cvnvVQ%3D
120. Ranasinha C, Assoufi B, Shak S, et al (1993) Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 342:199-202 10.1016/ 0140-6736(93)92297-7
121. Shah PL, Scott SF, Fuchs HJ, et al (1995) Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 50:333-338 1:STN:280:ByqA3cvkvVc%3D
122. Wilmott RW, Amin RS, Colin AA, et al (1996) Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 153:1914-1917 1:STN:280:BymB2sbnvVY%3D
123. Nasr SZ, Kuhns LR, Brown RW, et al (2001) Use of computerized tomography and chest X-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: A preliminary study. Pediatr Pulmonol 31:377-382 10.1002/ppul.1061
124. Robinson M, Regnis JA, Bailey DL, et al (1996) Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 153:1503-1509 1:STN:280:BymB3M%2FhvFY%3D
125. Daviskas E, Robinson M, Anderson SD, et al (2002) Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J Aerosol Med 15:331-341 10.1089/089426802760292681
126. Wark PA, McDonald V (2000) Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev: CD001506
127. Bisgaard H, Pedersen SS, Nielsen KG, et al (1997) Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. Am J Respir Crit Care Med 156:1190-1196 1:STN:280:DyaK1c%2FhtF2rtA%3D%3D
128. Balfour-Lynn IM, Klein NJ, Dinwiddie R (1997) Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 77:124-130 1:STN:280:ByiH2cnovF0%3D
129. Eigen H, Rosenstein BJ, FitzSimmons S, et al (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126:515-523 1:STN:280:ByqB3MzovVc%3D
130. Konstan MW, Byard PJ, Hoppel CL, et al (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332:848-854 10.1056/NEJM199503303321303
131. Oermann CM, Sockrider MM, Konstan MW (1999) The use of anti-inflammatory medications in cystic fibrosis: Trends and physician attitudes. Chest 115:1053-1058 10.1378/chest.115.4.1053
132. Schidlow DV, Taussig LM, Knowles MR (1993) Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 15:187-198 1:STN:280:ByyA3Mjjs1A%3D
133. Wood BP (1997) Cystic fibrosis. Radiology 204:1-10 1:STN:280:ByiA2cbitV0%3D
134. Ruzal-Shapiro C (1998) Cystic fibrosis An overview. Radiol Clin N Am 36:143-161 1:STN:280:DyaK1c7islShsg%3D%3D
135. JP Kuhn 2004 Diseases of airways and abnormalities of pulmonary aeration. In JP Kuhn, TL Slovis, JO Haller (eds) Caffey's pediatric diagnostic imaging. Mosby St. Louis pp. 929-982
136. van der Put JM, Meradji M, Danoesastro D, et al (1982) Chest radiographs in cystic fibrosis. A follow-up study with application of a quantitative system. Pediatr Radiol 12:57-61 10.1007/BF00972431
137. Brasfield D, Hicks G, Soong S, et al (1979) The chest roentgenogram in cystic fibrosis: A new scoring system. Pediatrics 63:24-29 1:STN:280:CSaC2sbltVI%3D
138. Conway SP, Pond MN, Bowler I, et al (1994) The chest radiograph in cystic fibrosis: A new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 49:860-862 1:STN:280:ByqD38nntF0%3D
139. Weatherly MR, Palmer CG, Peters ME, et al (1993) Wisconsin cystic fibrosis chest radiograph scoring system. Pediatrics 91:488-495 1:STN:280:ByyC2c7jtFw%3D
140. Shwachman H, Kulczycki LL (1958) Long-term study of 105 patients with cystic fibrosis. Am J Dis Child 96:6-15 1:STN:280:CyeD1cjmvV0%3D
141. Chrispin AR, Norman AP (1974) The systematic evaluation of a chest radiograph in CF. Pediatr Radiol 2:101-106 10.1007/BF01314939
142. Terheggen-Lagro S, Truijens N, van Poppel N, et al (2003) Correlation of six different cystic fibrosis chest radiograph scoring systems with clinical parameters. Pediatr Pulmonol 35:441-445 10.1002/ppul.10280
143. Koscik RE, Kosorok MR, Farrell PM, et al (2000) Wisconsin cystic fibrosis chest radiograph scoring system: Validation and standardization for application to longitudinal studies. Pediatr Pulmonol 29:457-467 10.1002/(SICI)1099-0496(200006)29:6<457::AID-PPUL8>3.0.CO;2-9
144. Cleveland RH, Neish AS, Zurakowski D, et al (1998) Cystic fibrosis: A system for assessing and predicting progression. AJR 170:1067-1072 1:STN:280:DyaK1c7ptFSqsw%3D%3D
145. Lynch DA, Brasch RC, Hardy KA, et al (1990) Pediatric pulmonary disease: Assessment with high-resolution ultrafast CT. Radiology 176:243-248 1:STN:280:By%2BB1c%2FnsVM%3D
146. Nathanson I, Conboy K, Murphy S, et al (1991) Ultrafast computerized tomography of the chest in cystic fibrosis: A new scoring system. Pediatr Pulmonol 11:81-86 1:STN:280:By2D38%2FgtVM%3D
147. Bhalla M, Turcios N, Aponte V, et al (19901) Cystic fibrosis: Scoring system with thin-section CT. Radiology 179:783-788 1:STN:280:By6B38jkvF0%3D
148. Shah RM, Sexauer W, Ostrum BJ, et al (1997) High-resolution CT in the acute exacerbation of cystic fibrosis: Evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR 169:375-380 1:STN:280:ByiA1cnmsVw%3D
149. Brody AS (1998) Cystic fibrosis: When should high-resolution computed tomography of the chest be obtained?. Pediatrics 101:1071 10.1542/ peds.101.6.1071
150. de Jong PA, Nakano Y, Lequin MH, et al (2004) Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 23:93-97 10.1183/09031936.03.00006603
151. Donnelly LF, Emery KH, Brody AS, et al (2001) Minimizing radiation dose for pediatric body applications of single-detector helical CT: Strategies at a large children's hospital. AJR 176:303-306 1:STN:280:DC%2BD3M3isVWktA%3D%3D
152. Paterson A, Frush DP, Donnelly LF (2001) Helical CT of the body: Are settings adjusted for pediatric patients? AJR 176:297-301 1:STN:280:DC%2BD3M3isVWktw%3D%3D
153. Frush DP, Yoshizumi TT, Paulson EK, et al (2001) Radiation dose from helical CT in children: Comparison of multi-slice and single-slice protocols (abstract). Radiology 221:246
154. Frush DP, Applegate K (2004) Computed tomography and radiation: Understanding the issues. J Am Coll Radiol 1:113-119 10.1016/ j.jacr.2003.11.012
155. Fricke BL, Donnelly LF, Frush DP, et al (2003) In-plane bismuth breast shields for pediatric CT: Effects on radiation dose and image quality using experimental and clinical data. AJR 180:407-411 12540443
156. Long FR, Castile RG, Brody AS, et al (1999) Lungs in infants and young children: Improved thin-section CT with a noninvasive controlled-ventilation technique - Initial experience. Radiology 212:588-593 1:STN:280:DyaK1MzlvVemsQ%3D%3D
157. Long FR, Castile RG (2001) Technique and clinical applications of full-inflation and end-exhalation controlled-ventilation chest CT in infants and young children. Pediatr Radiol 31:413-422 10.1007/ s002470100462
158. Long FR (2001) High-resolution CT of the lungs in infants and young
159. Robinson TE, Leung AN, Moss RB, et al (1999) Standardized high-resolution CT of the lung using a spirometer-triggered electron beam CT scanner. AJR 172:1636-1638 1:STN:280:DyaK1M3nslyjug%3D%3D
160. Robinson TE, Leung AN, Northway WH, et al (2001) Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. J Pediatr 138:553-559 10.1067/mpd.2001.111820
161. Long FR, Williams RS, Adler BH, et al (2003) Effect of tidal breathing and lung inflation on thin-section CT diagnosis of bronchial abnormalities and air trapping in infants with cystic fibrosis. Available at http://rsna2003.rsna.org/rsna2003/VBK/conference/ event_display.cfm?em_id=3100870. Cited 24 July 2004
162. Goris ML, Zhu HJ, Blankenberg F, et al (2003) An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Chest 123:1655-1663 10.1378/chest.123.5.1655
163. Santamaria F, Grillo G, Guidi G, et al (1998) Cystic fibrosis: When should high-resolution computed tomography of the chest be obtained? Pediatrics 101:908-913 10.1542/peds.101.5.908
164. Helbich TH, Heinz-Peer G, Fleischmann D, et al (1999) Evolution of CT findings in patients with cystic fibrosis. AJR 173:81-88 1:STN:280:DyaK1MzitlagsQ%3D%3D
165. Oikonomou A, Manavis J, Karagianni P, et al (2002) Loss of FEV1 in cystic fibrosis: Correlation with HRCT features. Eur Radiol 12:2229-2235 10.1007/s00330-001-1211-3
166. Maffessanti M, Candusso M, Brizzi F, et al (1996) Cystic fibrosis in children: HRCT findings and distribution of disease. J Thorac Imaging 11:27-38 1:STN:280:BymA28nmsVM%3D
167. Brody AS, Molina PL, Klein JS, et al (1999) High-resolution computed tomography of the chest in children with cystic fibrosis: Support for use as an outcome surrogate. Pediatr Radiol 29:731-735 10.1007/ s002470050684
168. Castile RG, Long FR, Flucke RL, et al (2000) Correlation of structural and functional abnormalities in the lungs of infants with cystic fibrosis. Pediatr Pulmonol Suppl 20:295
169. de Jong PA, Ottink MD, Robben SG, et al (2004) Pulmonary disease assessment in cystic fibrosis: Comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 231:434-439 15064392
170. Robinson TE, Leung AN, Northway WH, et al (2003) Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. Am J Respir Crit Care Med 168:588-593 10.1164/ rccm.200209-1093OC
171. Brody AS (2004) Early morphologic changes in the lungs of asymptomatic infants and young children with cystic fibrosis. J Pediatr 144:145-146 10.1016/j.jpeds.2003.11.008
172. Bedrossian CW, Greenberg SD, Singer DB, et al (1976) The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 7:195-204 1:STN:280:CSmC28nlt1E%3D
173. Long FR, Williams RS, Castile RG (2004) Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 144:154-161 10.1016/j.jpeds.2003.09.026
174. Dakin CJ, Pereira JK, Henry RL, et al (2002) Relationship between sputum inflammatory markers, lung function, and lung pathology on high-resolution computed tomography in children with cystic fibrosis. Pediatr Pulmonol 33:475-482 10.1002/ppul.10109
175. Goldin JG, Tashkin DP, Kleerup EC, et al (1999) Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: Assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 104:S258-S267 1:CAS:528:DC%2BD3cXjt1ynsA%3D%3D
176. Bonnel AS, Song SM, Kesavarju K, et al (2004) Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatr Pulmonol 38:396-405 10.1002/ppul.20091
177. Donnelly LF, Gelfand MJ, Brody AS, et al (1997) Comparison between morphologic changes seen on high-resolution CT and regional pulmonary perfusion seen on SPECT in patients with cystic fibrosis. Pediatr Radiol 27:920-925 10.1007/s002470050272
178. Jaffe A, Hamutcu R, Dhawan RT, et al (2001) Routine ventilation scans in children with cystic fibrosis: Diagnostic usefulness and prognostic value. Eur J Nucl Med 28:1313-1318 10.1007/s002590100573
179. 3He-enhanced and conventional proton MR imaging in the lung - Preliminary observations. Radiology 212:885-889 1:STN:280:DyaK1MvgslKquw%3D%3D
180. Tsui LC, Durie P (1997) Genotype and phenotype in cystic fibrosis. Hosp Pract (Off Ed) 32:115-118 (see also 123-119, 134, passim) 1:STN:280:DyaK1MzlvVemsQ%3D%3D